4D Molecular Therapeutics promoted Fred Kamal to president and COO of the company Tuesday afternoon.

“Fred’s vast experience and dedication to 4DMT’s mission will propel our continued success and growth as he takes on this expanded role,” 4DMT CEO David Kirn, MD, said in a statement. 

The clinical-stage biotherapeutics company also appointed Noriyuki Kasahara, MD, PhD to its board of directors. Kasahara is the Alvera L. Kan Endowed Chair of Neurological Surgery and Radiation Oncology at the University of California San Francisco.